“While orphan drugs’ share of the $880-billion global pharmaceuticals market remains small—at $50 billion as of the end of 2011, or just 6% of the total—their growth curve has been steep. Thomson Reuters reports that between 2001 and 2010, orphan drugs posted a compound annual growth rate of 25.8%, outstripping the 20.1% CAGR returned by a matched non-orphan control group. With these kinds of eye-popping profits being raked in by orphan drug makers, the investment world has taken notice.”
http://www.caseyresearch.com/cdd/orphans-adding-company-value-in-the-biotech-space
